The following IPOs are expected to price this week:
Aldeyra Therapeutics (ALDX), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to raise $25 million by offering 2.3 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Aldeyra Therapeutics would command a market value of $75 million. Aldeyra Therapeutics, which was founded in 2004, booked $0 million in sales over the last 12 months. The Burlington, MA-based company plans to list on the NASDAQ under the symbol ALDX. Aegis Capital is the lead bookrunner on the deal.
Quotient (QTNT), which is developing a diagnostics test for grouping and disease screening blood samples, plans to raise $50 million by offering 5.0 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Quotient would command a market value of $149 million. Quotient, which was founded in 2007, booked $19 million in sales over the last 12 months. The Midlothian, United Kingdom-based company plans to list on the NASDAQ under the symbol QTNT. UBS Investment Bank, Baird and Cowen & Company are the joint bookrunners on the deal. (Revised terms on 4/14/14. Previously planned to offer 5.0mm shares at $14-$16.)
SCYNEXIS (SCYX), a biotech developing treatments for life-threatening fungal infections, plans to raise $55 million by offering 7.3 million shares at a price range of $7.00 to $8.00. At the midpoint of the proposed range, SCYNEXIS would command a market value of $143 million. SCYNEXIS, which was founded in 1999, booked $17 million in sales over the last 12 months. The Durham, NC-based company plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. (Revised terms on 4/2/14. Previously planned to offer 4.2mm shares at $12-$14.)
Viggle (VGGL), a mobile app that rewards users for watching TV and listening to music, plans to raise $50 million by offering 2.1 million shares at a price of $23.50. At the midpoint of the proposed range, Viggle would command a market value of $313 million. Viggle, which was founded in 2011, booked $17 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol VGGL. Ladenburg Thalmann & Co. and Roth Capital are the lead bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 10 IPO pricings. TriVascular Technologies (TRIV), which markets the smallest and most versatile stent grafts for endovascular aortic repair, was the week's winner, ending up 19% from its IPO price.
